Chronic obstructive pulmonary disease and comorbidities’ influence on mortality in non-small cell lung cancer patients

Media, Ara Shwan; Persson, Martin E.; Tajhizi, Navid; Weinreich, Ulla Møller

doi:10.1080/0284186x.2019.1612942

Cited by 11 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, COPD was not associated with higher mortality in either uni-nor multi-variate analysis. These findings are in line with the results obtained from other authors who could corroborate that COPD had no impact on the mortality of patients with NSCLC [29][30][31].…”

Section: Discussionsupporting

confidence: 93%

“…In contrast, after inclusion of patients with all tumor stages, COPD might not affect the postoperative survival. This could explain this divergent finding together with a relatively small study population [29,31]. In this context, all authors endorsed that the retrospective study design using clinical records as data resource represents a potential limitation [29][30][31].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Prognostic Long-Term Impact of Chronic Obstructive Pulmonary Disease and Postoperative Mucostasis in Patients with Curatively Resected Non-Small Cell Lung Cancer

Lindenmann

Fediuk

Fink-Neuboeck

et al. 2023

Cells

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) serves as risk factor for the development of lung cancer and seems to have a prognostic impact after surgery for non-small cell lung cancer (NSCLC). The aim was to investigate the impact of COPD and postoperative mucostasis on the long-term survival after resected NSCLC. We retrospectively reviewed the data from 342 patients with curatively resected NSCLC. The prognostic long-term impact of COPD and postoperative mucostasis on overall survival (OS), recurrence free survival (RFS) and cancer specific survival (CSS) was calculated using univariable and multivariable Cox regression analyses. We found that 52.3% suffered from COPD and 25.4% had postoperative mucostasis. COPD was significantly more common among smokers (59.9%) compared with non-smokers (21.3%), (p < 0.001). There was a significant relationship between COPD and postoperative mucostasis (p = 0.006) and between smoking and mucostasis (p = 0.023). Patients with postoperative mucostasis had a significantly worse OS (p < 0.001), RFS (p = 0.009) and CSS (p = 0.008). The present analysis demonstrated that postoperative mucostasis, but not COPD, was associated with both worse short- and long-term outcomes for OS, RFS and CSS in curatively resected NSCLC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

The Prognostic Long-Term Impact of Chronic Obstructive Pulmonary Disease and Postoperative Mucostasis in Patients with Curatively Resected Non-Small Cell Lung Cancer

Lindenmann

Fediuk

Fink-Neuboeck

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Patients with certain types of cancer often have various comorbidities, making them vulnerable ( 50 ). Patients affected by lung cancer and/or SCCHN, for example, typically have a long history of smoking and, in the case of SCCHN, heavy drinkers; both of which associated with pulmonary, liver and cardiac diseases ( 18 , 51 ). The present analysis highlighted that patients affected by SCCHN are a particularly susceptible population, since they frequently have several comorbidities at diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID‑19

et al. 2021

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the recent Coronavirus Disease 2019 (COVID-19) pandemic, which has spread all over the world over the past year. Comorbidities appear to affect the prognosis of patients with such diseases, but the impact of cancer on the course of SARS-CoV2 has remained largely elusive. The aim of the present study is to analyze the outcome of patients affected by squamous cell carcinoma of the head and neck (SCCHN) and a number of their comorbidities, if infected with SARS-CoV2. The clinical data of 100 patients affected by SCCHN, who were undergoing treatment or who had finished their oncologic treatment in the past 6 months, were retrospectively collected and analysed. For each patient, the Charlson Comorbidity Index (CCI) was calculated to provide a score assessing the real weight of comorbidities on the patient's outcome at the time of diagnosis. It was discovered that these patients, besides the SCCHN, frequently presented at diagnosis with several other comorbidities, including hypertension, type 2 diabetes, cardiac arrhytmia, chronic obstructive pulmonary disease and various forms of vasculopathy (and thus a poor CCI). This feature suggest that, given the high frequency of various comorbidities in patients with SCCHN, additional SARS-CoV2 infection could have particularly devastating consequences.

show abstract

“…Lung cancer is among the predominant causes of death worldwide and takes the top spot in cancer-related deaths (Refs 88 , 89 ). Both COPD and lung cancer are CS-related diseases and are described as risk factors of each other, while commonly occurring as co-morbid conditions (Refs 90 , 91 , 92 ). Since NOTCH signalling is one of the key regulators of cell fate, with intricate control over cell proliferation, survival, differentiation and apoptosis, it is unsurprising that NOTCH is strongly related to lung cancer (Refs 54 , 93 , 94 , 95 , 96 ).…”

Section: Notch3 Signalling and Acute Or Chronic Lung Diseasementioning

confidence: 99%

The emerging role of NOTCH3 receptor signalling in human lung diseases

Bodas

Bharathiraja

Karmouty‐Quintana

et al. 2022

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

The mammalian respiratory system or lung is a tree-like branching structure, and the main site of gas exchange with the external environment. Structurally, the lung is broadly classified into the proximal (or conducting) airways and the distal alveolar region, where the gas exchange occurs. In parallel with the respiratory tree, the pulmonary vasculature starts with large pulmonary arteries that subdivide rapidly ending in capillaries adjacent to alveolar structures to enable gas exchange. The NOTCH signalling pathway plays an important role in lung development, differentiation and regeneration post-injury. Signalling via the NOTCH pathway is mediated through activation of four NOTCH receptors (NOTCH1-4), with each receptor capable of regulating unique biological processes. Dysregulation of the NOTCH pathway has been associated with development and pathophysiology of multiple adult acute and chronic lung diseases. This includes accumulating evidence that alteration of NOTCH3 signalling plays an important role in the development and pathogenesis of chronic obstructive pulmonary disease, lung cancer, asthma, idiopathic pulmonary fibrosis and pulmonary arterial hypertension. Herein, we provide a comprehensive summary of the role of NOTCH3 signalling in regulating repair/regeneration of the adult lung, its association with development of lung disease and potential therapeutic strategies to target its signalling activity.

show abstract

Chronic obstructive pulmonary disease and comorbidities’ influence on mortality in non-small cell lung cancer patients

Cited by 11 publications

References 14 publications

The Prognostic Long-Term Impact of Chronic Obstructive Pulmonary Disease and Postoperative Mucostasis in Patients with Curatively Resected Non-Small Cell Lung Cancer

The Prognostic Long-Term Impact of Chronic Obstructive Pulmonary Disease and Postoperative Mucostasis in Patients with Curatively Resected Non-Small Cell Lung Cancer

Patients affected by squamous cell carcinoma of the head and neck: A population particularly prone to developing severe forms of COVID‑19

The emerging role of NOTCH3 receptor signalling in human lung diseases

Contact Info

Product

Resources

About